Show simple item record

dc.contributor.authorKhambata-Ford, Shirin
dc.contributor.authorZalcberg, John R.
dc.contributor.authorSimes, John
dc.contributor.authorKarapetis, Christos Stelios
dc.contributor.authorBardelli, Alberto
dc.contributor.authorTejpar, Sabine
dc.contributor.authorDe Roock, Wendy
dc.contributor.authorJonker, Derek
dc.contributor.authorDi Nicolantonio, Federica
dc.contributor.authorSartore-Bianchi, Andrea
dc.contributor.authorTu, Dongsheng
dc.contributor.authorSiena, Salvatore
dc.contributor.authorLamba, Simona
dc.contributor.authorArena, Sabrina
dc.contributor.authorFrattini, Milo
dc.contributor.authorPiessevaux, Hubert
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorO'Callaghan, Chris J
dc.date.accessioned2014-09-30T06:11:12Z
dc.date.available2014-09-30T06:11:12Z
dc.date.issued2010en_US
dc.identifier.citationDe Roock, W., Jonker, D., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., et al. (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA-Journal of The American Medical Association, 304 pp. 1812-1820.en
dc.identifier.issn0098-7484en_US
dc.identifier.urihttp://hdl.handle.net/2328/32893
dc.titleAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximaben_US
dc.typeArticleen_US
dc.identifier.rmid2006021077en_US
dc.identifier.doihttps://doi.org/10.1001/jama.2010.1535en
dc.subject.forgroup1112 Oncology and Carcinogenesisen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record